Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
429.820USD
+4.820+1.13%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
109.24BMarket Cap
25.28P/E TTM
More Details of Vertex Pharmaceuticals Inc Company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Info
Ticker SymbolVRTX
Company nameVertex Pharmaceuticals Inc
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Number of employees6100
Security typeOrdinary Share
Fiscal year-endJul 24
Address50 Northern Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16173416393
Websitehttps://www.vrtx.com/
Ticker SymbolVRTX
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Company Executives of Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
--
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
29.50K
+12.65%
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
21.83K
-4.48%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
17.74K
-112.72%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.30K
--
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
--
Mr. Michel Lagarde
Mr. Michel Lagarde
Independent Director
Independent Director
1.13K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
--
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
29.50K
+12.65%
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
21.83K
-4.48%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
17.74K
-112.72%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
10.31B
86.15%
ALYFTREK
837.80M
7.00%
Other CF products
820.10M
6.85%
By RegionUSD
Name
Revenue
Proportion
United States
7.55B
63.06%
Europe
3.46B
28.91%
Other
992.40M
8.29%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
TRIKAFTA
10.31B
86.15%
ALYFTREK
837.80M
7.00%
Other CF products
820.10M
6.85%
Shareholding Stats
Updated: Thu, Feb 19
Updated: Thu, Feb 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Capital World Investors
10.05%
The Vanguard Group, Inc.
9.07%
Capital Research Global Investors
6.82%
BlackRock Institutional Trust Company, N.A.
6.00%
State Street Investment Management (US)
4.61%
Other
63.45%
Shareholders
Shareholders
Proportion
Capital World Investors
10.05%
The Vanguard Group, Inc.
9.07%
Capital Research Global Investors
6.82%
BlackRock Institutional Trust Company, N.A.
6.00%
State Street Investment Management (US)
4.61%
Other
63.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
60.09%
Investment Advisor/Hedge Fund
28.11%
Pension Fund
2.27%
Research Firm
2.19%
Bank and Trust
2.05%
Sovereign Wealth Fund
1.33%
Hedge Fund
1.27%
Individual Investor
0.17%
Insurance Company
0.08%
Other
2.42%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
3075
247.47M
97.50%
-4.59M
2025Q4
2995
248.62M
97.99%
-4.56M
2025Q3
2933
249.27M
98.24%
-2.14M
2025Q2
2933
252.71M
98.56%
+2.47M
2025Q1
2977
252.24M
98.22%
-39.54K
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital World Investors
25.51M
10.04%
-400.40K
-1.55%
Dec 31, 2025
The Vanguard Group, Inc.
23.99M
9.44%
-113.70K
-0.47%
Dec 31, 2025
Capital Research Global Investors
17.32M
6.82%
+763.06K
+4.61%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
15.24M
6%
+768.21K
+5.31%
Dec 31, 2025
State Street Investment Management (US)
11.69M
4.6%
+83.54K
+0.72%
Dec 31, 2025
Geode Capital Management, L.L.C.
5.98M
2.35%
+8.16K
+0.14%
Dec 31, 2025
Invesco Capital Management (QQQ Trust)
5.40M
2.12%
-130.10K
-2.35%
Feb 28, 2026
Capital International Investors
4.73M
1.86%
+44.54K
+0.95%
Dec 31, 2025
JP Morgan Asset Management
4.54M
1.79%
+150.76K
+3.44%
Dec 31, 2025
AllianceBernstein L.P.
4.50M
1.77%
-26.10K
-0.58%
Dec 31, 2025
View more
Related ETFs
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Name
Proportion
VanEck Biotech ETF
9.71%
ProShares Ultra Nasdaq Biotechnology
8.83%
Invesco Nasdaq Biotechnology ETF
8.76%
iShares Biotechnology ETF
7.43%
Invesco Biotechnology & Genome ETF
5.35%
Natixis Loomis Sayles Focused Growth ETF
4.48%
First Trust NASDAQ Pharmaceuticals ETF
4.23%
First Trust NYSE Arca Biotechnology Index Fund
3.5%
Franklin Genomic Advancements ETF
3.33%
Simplify Health Care ETF
3.25%
View more
VanEck Biotech ETF
Proportion9.71%
ProShares Ultra Nasdaq Biotechnology
Proportion8.83%
Invesco Nasdaq Biotechnology ETF
Proportion8.76%
iShares Biotechnology ETF
Proportion7.43%
Invesco Biotechnology & Genome ETF
Proportion5.35%
Natixis Loomis Sayles Focused Growth ETF
Proportion4.48%
First Trust NASDAQ Pharmaceuticals ETF
Proportion4.23%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.5%
Franklin Genomic Advancements ETF
Proportion3.33%
Simplify Health Care ETF
Proportion3.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
